Real-world incidence of kidney manifestations in patients treated with new tyrosine kinase inhibitors. Presented at: Kidney Week 2022; November 3-6, Orlando, Florida. Abstract FR-PO215.

Hepatocellular Carcinoma: Pick the Winner -- Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations – An ASCO Reading Room selection December 15, 2022 • 2 min read ...

Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ...